Study of Genakumab for lung scarring from connective tissue disease
Part of Bones, joints & muscles, Immune system & allergy, Lungs & breathing clinical trials.
This study tests a new injected medication (Genakumab) for people with connective tissue disease-related lung scarring. It aims to see if it helps stabilize or improve lung function safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rheumatoid arthritis or systemic sclerosis, confirmed by your doctor
- You have been diagnosed with interstitial lung disease (lung scarring) in the last year
- Your lung function tests show at least 40% of normal breathing capacity
- You are not taking high doses of steroids (prednisone above 15 mg/day)
- You have not used certain strong medications (like rituximab or tofacitinib) recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called GenSci120 for people with moderate to severe rheumatoid arthritis who haven't improved enough after trying at least one standard arthritis medication. The goal is to see if this treatment can help reduce joint pain and swelling.
This trial tests whether a new class of drugs called JAK inhibitors (which block inflammation signals) is better than a standard treatment (calcineurin inhibitors) for people with lung scarring (interstitial lung disease) caused by Anti-Synthetase Syndrome. It is for people who have not yet taken any immune-suppressing medications for this condition.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This study tests a new drug called GenSci120, given as multiple injections under the skin, to see if it is safe in healthy adults. It will also measure how the drug moves through the body and how it affects certain immune markers.
This trial tests a new drug, GenSci136, in healthy adults to see if it's safe and how the body processes it. If you qualify, you would receive the drug and be monitored for side effects.
Hear when a new Systemic Sclerosis Associated Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.